Article List
List all articles in the database by earliest discovery_date
GET /articles/
{ "count": 34775, "next": "http://api.gregory-ms.com/articles/?page=2", "previous": null, "results": [ { "article_id": 294673, "title": "Effects of atidarsagene autotemcel gene therapy on peripheral nerves in late-infantile metachromatic leukodystrophy", "summary": "<jats:title>Abstract</jats:title>\n <jats:p>This study evaluates the efficacy of arsa-cel gene therapy (GT) in mitigating the severity and progression of peripheral neuropathy as assessed by nerve conduction velocity (NCV) in individuals affected by late-infantile metachromatic leukodystrophy (LI-MLD).</jats:p>\n <jats:p>This is a post-hoc analysis conducted on pre-symptomatic patients affected by LI-MLD treated with ex vivo autologous hematopoietic stem cell GT (atidarsagene autotemcel, “arsa-cel”) in the context of prospective open-label, single-arm, interventional trials and expanded access programs. All patients were followed longitudinally with nerve conduction studies (NCSs) of peripheral motor (ulnar - UN, deep peroneal - DPN) and sensory (median - MN, sural - SN) nerves. These results were compared with those from a control group of untreated patients (NHx) studied with the same standardized protocol. We then analyzed the effects of baseline characteristics (age at treatment, severity of neuropathy pre-treatment expressed as age-matched NCV Z-scores) and arylsulfatase A (ARSA) enzyme activity (measured in peripheral blood myeloid CD15+ cells post treatment) on NCVs of treated patients. The primary endpoint of this post-hoc analysis was NCV, reflecting severity of demyelinating neuropathy. Changes in dermal nerve histopathology in skin biopsies were used as an exploratory outcome.</jats:p>\n <jats:p>Fifteen treated and 16 NHx patients were included in the analyses, with a median age (IQR) at treatment of 13 (9.1;14.5) months. At 36 months of age, treated patients showed higher estimated NCVs in all nerves compared to age-matched controls (∼15 m/s difference in motor nerves). Peripheral neuropathy was observed in the majority of treated patients at their pre-treatment examination (age range 7.3-17.4 months). Severity of pre-treatment neuropathy in treated patients did not have an effect on NCV values at 2 years post-GT, or on the rate of NCV slowing afterwards. A younger age at treatment was associated with higher NCVs of motor UN and sensory MN 2 years post-GT. Overall, ARSA levels in CD15+ cells correlated with NCVs of motor DPN at 2 years post-GT, and ARSA levels were associated with a slower decrease or a slight increase in NCVs of the DPN, UN and MN nerves afterwards.</jats:p>\n <jats:p>In summary, peripheral neuropathy assessed by NCV is significantly ameliorated in LI patients treated with arsa-cel compared to untreated patients of similar age. In addition to the potential role of early age at treatment in the preservation of myelin, supraphysiological ARSA levels may slow demyelination of the DPN and other peripheral nerves. Arsa-cel may exert a stronger effect on NCV than allogeneic hematopoietic stem cell transplantation due to its greater ARSA expression.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/40286327/?fc=20240608182355&ff=20250427072511&v=2.18.0.post9+e462414", "published_date": "2025-04-26T10:00:00Z", "sources": [ "PubMed CNS Regenerate" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 2, "subject_name": "CNS Regeneration", "description": "https://pubmed.ncbi.nlm.nih.gov/rss/search/1dmEOdK-P_-UBN_co2XahWMyPwt10E-2wAci7qgyqB1wWIwkJY/?limit=100&utm_campaign=pubmed-2&fc=20240608182355\r\n\r\n((\"Central Nervous System Regeneration\" OR \"Neuroregeneration\" OR \"Neural Regeneration\" OR \"Central Nervous System Repair\") \r\nOR (\"Myelination\" OR \"Remyelination\" OR \"Myelin Repair\" OR \"Oligodendrocyte Differentiation\" OR \"Oligodendrocyte Progenitor Cells\" OR \"Myelin Regeneration\") \r\nOR (\"Stem Cells and Myelin Production\" OR \"Neural Stem Cells\" OR \"Growth Factors for Myelin Regeneration\" OR \"Neurotrophic Factors\" OR \"Glial Cell Line-Derived Neurotrophic Factor\") \r\nOR (\"Gene Therapy for CNS Repair\" OR \"Gene Therapy for Myelination\" OR \"Molecular Targets for Myelin Regeneration\" OR \"Epigenetic Regulation of Myelination\") \r\nOR (\"Pharmacological Agents for CNS Regeneration\" OR \"Drugs Promoting Myelination\" OR \"Neuroprotective Agents\" OR \"Remyelinating Drugs\" OR \"Small Molecules for Myelin Repair\") \r\nOR (\"Novel Treatments for CNS Repair\" OR \"Emerging Therapies for Myelin Regeneration\"))", "team_id": 1 } ], "publisher": "Oxford University Press (OUP)", "container_title": "Brain", "authors": [ { "author_id": 407482, "given_name": "Alberto A", "family_name": "Zambon", "ORCID": "https://orcid.org/0000-0002-6539-5360", "country": null }, { "author_id": 407483, "given_name": "Paola M V", "family_name": "Rancoita", "ORCID": null, "country": null }, { "author_id": 372515, "given_name": "Angelo", "family_name": "Quattrini", "ORCID": "http://orcid.org/0000-0002-8226-8320", "country": null }, { "author_id": 407484, "given_name": "Calogera", "family_name": "Butera", "ORCID": null, "country": null }, { "author_id": 407485, "given_name": "Francesco", "family_name": "Gentile", "ORCID": null, "country": null }, { "author_id": 407486, "given_name": "Marcella", "family_name": "Facchini", "ORCID": null, "country": null }, { "author_id": 407487, "given_name": "Sara", "family_name": "Mazza", "ORCID": null, "country": null }, { "author_id": 407488, "given_name": "Salvatore", "family_name": "Recupero", "ORCID": null, "country": null }, { "author_id": 407489, "given_name": "Vera", "family_name": "Gallo", "ORCID": null, "country": null }, { "author_id": 407490, "given_name": "Andrew", "family_name": "Shenker", "ORCID": null, "country": null }, { "author_id": 407491, "given_name": "Nicholas D", "family_name": "Gollop", "ORCID": null, "country": null }, { "author_id": 266255, "given_name": "Ubaldo", "family_name": "Del Carro", "ORCID": null, "country": null }, { "author_id": 407492, "given_name": "Valeria", "family_name": "Calbi", "ORCID": null, "country": null }, { "author_id": 407493, "given_name": "Clelia", "family_name": "Di Serio", "ORCID": "https://orcid.org/0000-0001-6385-6058", "country": null }, { "author_id": 407494, "given_name": "Maria Grazia", "family_name": "Natali Sora", "ORCID": null, "country": null }, { "author_id": 380002, "given_name": "Massimo", "family_name": "Filippi", "ORCID": "https://orcid.org/0000-0002-5485-0479", "country": null }, { "author_id": 407495, "given_name": "Alessandro", "family_name": "Aiuti", "ORCID": "https://orcid.org/0000-0002-5398-1717", "country": null }, { "author_id": 359107, "given_name": "Francesca", "family_name": "Fumagalli", "ORCID": null, "country": null } ], "discovery_date": "2025-04-27T11:25:50.745869Z", "article_subject_relevances": [], "doi": "10.1093/brain/awaf157", "access": "restricted", "takeaways": "Arsa-cel gene therapy is effective in mitigating the severity and progression of peripheral neuropathy in people with late-infantile metachromatic leukodystrophy (LI-MLD).", "team_categories": [], "ml_predictions": [] }, { "article_id": 294672, "title": "Artemisinin alleviates ischemic stroke injury and promotes neurogenesis through PPARγ-mediated M2 polarization of microglia", "summary": "CONCLUSION: Our findings demonstrate that ART ameliorates IS injury and promotes neurogenesis mainly through PPARγ-mediated microglia M2 polarization. Therefore, ART can be considered a potential therapeutic drug for IS.", "link": "https://pubmed.ncbi.nlm.nih.gov/40286750/?fc=20240608182355&ff=20250427072511&v=2.18.0.post9+e462414", "published_date": "2025-04-26T10:00:00Z", "sources": [ "PubMed CNS Regenerate" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 2, "subject_name": "CNS Regeneration", "description": "https://pubmed.ncbi.nlm.nih.gov/rss/search/1dmEOdK-P_-UBN_co2XahWMyPwt10E-2wAci7qgyqB1wWIwkJY/?limit=100&utm_campaign=pubmed-2&fc=20240608182355\r\n\r\n((\"Central Nervous System Regeneration\" OR \"Neuroregeneration\" OR \"Neural Regeneration\" OR \"Central Nervous System Repair\") \r\nOR (\"Myelination\" OR \"Remyelination\" OR \"Myelin Repair\" OR \"Oligodendrocyte Differentiation\" OR \"Oligodendrocyte Progenitor Cells\" OR \"Myelin Regeneration\") \r\nOR (\"Stem Cells and Myelin Production\" OR \"Neural Stem Cells\" OR \"Growth Factors for Myelin Regeneration\" OR \"Neurotrophic Factors\" OR \"Glial Cell Line-Derived Neurotrophic Factor\") \r\nOR (\"Gene Therapy for CNS Repair\" OR \"Gene Therapy for Myelination\" OR \"Molecular Targets for Myelin Regeneration\" OR \"Epigenetic Regulation of Myelination\") \r\nOR (\"Pharmacological Agents for CNS Regeneration\" OR \"Drugs Promoting Myelination\" OR \"Neuroprotective Agents\" OR \"Remyelinating Drugs\" OR \"Small Molecules for Myelin Repair\") \r\nOR (\"Novel Treatments for CNS Repair\" OR \"Emerging Therapies for Myelin Regeneration\"))", "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Phytomedicine", "authors": [ { "author_id": 254431, "given_name": "Lin", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 407474, "given_name": "Huiqin", "family_name": "Hu", "ORCID": null, "country": null }, { "author_id": 407475, "given_name": "Weifeng", "family_name": "Jiang", "ORCID": null, "country": null }, { "author_id": 407476, "given_name": "Shihui", "family_name": "Mao", "ORCID": null, "country": null }, { "author_id": 407477, "given_name": "Zheng", "family_name": "Yang", "ORCID": null, "country": null }, { "author_id": 407478, "given_name": "Ting", "family_name": "Lan", "ORCID": null, "country": null }, { "author_id": 407479, "given_name": "Xiaowei", "family_name": "Hu", "ORCID": null, "country": null }, { "author_id": 407480, "given_name": "Yan", "family_name": "Fang", "ORCID": null, "country": null }, { "author_id": 362313, "given_name": "Lanxi", "family_name": "Xu", "ORCID": null, "country": null }, { "author_id": 362312, "given_name": "Jiadong", "family_name": "Xu", "ORCID": null, "country": null }, { "author_id": 396625, "given_name": "Yan", "family_name": "Yang", "ORCID": "https://orcid.org/0009-0007-7856-7989", "country": null }, { "author_id": 362315, "given_name": "Weiru", "family_name": "Jiang", "ORCID": null, "country": null }, { "author_id": 407481, "given_name": "Lisheng", "family_name": "Chu", "ORCID": "https://orcid.org/0000-0001-5149-5881", "country": null } ], "discovery_date": "2025-04-27T11:25:44.281162Z", "article_subject_relevances": [], "doi": "10.1016/j.phymed.2025.156769", "access": "open", "takeaways": "", "team_categories": [], "ml_predictions": [] }, { "article_id": 294671, "title": "Tumor-associated Schwann cells as new therapeutic target in non-neurological cancers", "summary": "Cancer neuroscience, a burgeoning field, investigates the complex interactions between cancer and the nervous system, emphasizing how cancer cells exploit neuronal components for growth and metastasis. Tumor-associated Schwann cells (TASc) have emerged as crucial players in the progression of highly innervated cancers, highlighting the intricate relationship between the tumor microenvironment (TME) and the nervous system. This review concludes how TASc, as the most abundant glial cell in the...", "link": "https://pubmed.ncbi.nlm.nih.gov/40286840/?fc=20240608182355&ff=20250427072511&v=2.18.0.post9+e462414", "published_date": "2025-04-26T10:00:00Z", "sources": [ "PubMed CNS Regenerate" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 2, "subject_name": "CNS Regeneration", "description": "https://pubmed.ncbi.nlm.nih.gov/rss/search/1dmEOdK-P_-UBN_co2XahWMyPwt10E-2wAci7qgyqB1wWIwkJY/?limit=100&utm_campaign=pubmed-2&fc=20240608182355\r\n\r\n((\"Central Nervous System Regeneration\" OR \"Neuroregeneration\" OR \"Neural Regeneration\" OR \"Central Nervous System Repair\") \r\nOR (\"Myelination\" OR \"Remyelination\" OR \"Myelin Repair\" OR \"Oligodendrocyte Differentiation\" OR \"Oligodendrocyte Progenitor Cells\" OR \"Myelin Regeneration\") \r\nOR (\"Stem Cells and Myelin Production\" OR \"Neural Stem Cells\" OR \"Growth Factors for Myelin Regeneration\" OR \"Neurotrophic Factors\" OR \"Glial Cell Line-Derived Neurotrophic Factor\") \r\nOR (\"Gene Therapy for CNS Repair\" OR \"Gene Therapy for Myelination\" OR \"Molecular Targets for Myelin Regeneration\" OR \"Epigenetic Regulation of Myelination\") \r\nOR (\"Pharmacological Agents for CNS Regeneration\" OR \"Drugs Promoting Myelination\" OR \"Neuroprotective Agents\" OR \"Remyelinating Drugs\" OR \"Small Molecules for Myelin Repair\") \r\nOR (\"Novel Treatments for CNS Repair\" OR \"Emerging Therapies for Myelin Regeneration\"))", "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Cancer Letters", "authors": [ { "author_id": 397614, "given_name": "Leyi", "family_name": "Huang", "ORCID": null, "country": null }, { "author_id": 407468, "given_name": "Ge", "family_name": "Qi", "ORCID": null, "country": null }, { "author_id": 407469, "given_name": "Guangyao", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 407470, "given_name": "Jinxin", "family_name": "Duan", "ORCID": null, "country": null }, { "author_id": 407471, "given_name": "Cao", "family_name": "Dai", "ORCID": null, "country": null }, { "author_id": 407472, "given_name": "Yanan", "family_name": "Lu", "ORCID": null, "country": null }, { "author_id": 407473, "given_name": "Quanbo", "family_name": "Zhou", "ORCID": "https://orcid.org/0000-0001-9554-063X", "country": null } ], "discovery_date": "2025-04-27T11:25:40.124579Z", "article_subject_relevances": [], "doi": "10.1016/j.canlet.2025.217748", "access": "restricted", "takeaways": "Tumor-associated Schwann cells (TASc) have emerged as crucial players in the progression of highly innervated cancers. TASc", "team_categories": [], "ml_predictions": [] }, { "article_id": 294670, "title": "7,8-Dihydroxyflavone provides neuroprotection and rescues behavioral deficits in Angiostrongylus cantonensis-infected mice by ameliorating synaptic loss", "summary": "CONCLUSION: These findings suggested that 7,8-DHF could confer neuroprotective effects, particularly in mitigating synaptic loss in the presynaptic region, and alleviating behavioral deficits from infection without inducing cell death. We anticipate these results will aid in the treatment of angiostrongyliasis-induced neurological damage.", "link": "https://pubmed.ncbi.nlm.nih.gov/40287337/?fc=20240608182355&ff=20250427072511&v=2.18.0.post9+e462414", "published_date": "2025-04-26T10:00:00Z", "sources": [ "PubMed CNS Regenerate" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 2, "subject_name": "CNS Regeneration", "description": "https://pubmed.ncbi.nlm.nih.gov/rss/search/1dmEOdK-P_-UBN_co2XahWMyPwt10E-2wAci7qgyqB1wWIwkJY/?limit=100&utm_campaign=pubmed-2&fc=20240608182355\r\n\r\n((\"Central Nervous System Regeneration\" OR \"Neuroregeneration\" OR \"Neural Regeneration\" OR \"Central Nervous System Repair\") \r\nOR (\"Myelination\" OR \"Remyelination\" OR \"Myelin Repair\" OR \"Oligodendrocyte Differentiation\" OR \"Oligodendrocyte Progenitor Cells\" OR \"Myelin Regeneration\") \r\nOR (\"Stem Cells and Myelin Production\" OR \"Neural Stem Cells\" OR \"Growth Factors for Myelin Regeneration\" OR \"Neurotrophic Factors\" OR \"Glial Cell Line-Derived Neurotrophic Factor\") \r\nOR (\"Gene Therapy for CNS Repair\" OR \"Gene Therapy for Myelination\" OR \"Molecular Targets for Myelin Regeneration\" OR \"Epigenetic Regulation of Myelination\") \r\nOR (\"Pharmacological Agents for CNS Regeneration\" OR \"Drugs Promoting Myelination\" OR \"Neuroprotective Agents\" OR \"Remyelinating Drugs\" OR \"Small Molecules for Myelin Repair\") \r\nOR (\"Novel Treatments for CNS Repair\" OR \"Emerging Therapies for Myelin Regeneration\"))", "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Journal of Microbiology, Immunology and Infection", "authors": [ { "author_id": 407464, "given_name": "Kai-Yuan", "family_name": "Jhan", "ORCID": null, "country": null }, { "author_id": 407465, "given_name": "Kuang-Yao", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 383833, "given_name": "Pi-Kai", "family_name": "Chang", "ORCID": null, "country": null }, { "author_id": 346323, "given_name": "Cheng-Hsun", "family_name": "Chiu", "ORCID": null, "country": null }, { "author_id": 407466, "given_name": "Chih-Jen", "family_name": "Chou", "ORCID": null, "country": null }, { "author_id": 407467, "given_name": "Lian-Chen", "family_name": "Wang", "ORCID": null, "country": null } ], "discovery_date": "2025-04-27T11:25:36.275490Z", "article_subject_relevances": [], "doi": "10.1016/j.jmii.2025.04.001", "access": "open", "takeaways": "", "team_categories": [], "ml_predictions": [] }, { "article_id": 294669, "title": "Brain circuits that regulate social behavior", "summary": "Social interactions are essential for the survival of individuals and the reproduction of populations. Social stressors, such as social defeat and isolation, can lead to emotional disorders and cognitive impairments. Furthermore, dysfunctional social behaviors are hallmark symptoms of various neuropsychiatric disorders, including autism spectrum disorder (ASD) and post-traumatic stress disorder (PTSD). Consequently, understanding the neural circuit mechanisms underlying social behaviors has...", "link": "https://pubmed.ncbi.nlm.nih.gov/40287553/?fc=20240608182355&ff=20250427072511&v=2.18.0.post9+e462414", "published_date": "2025-04-26T10:00:00Z", "sources": [ "PubMed CNS Regenerate" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 2, "subject_name": "CNS Regeneration", "description": "https://pubmed.ncbi.nlm.nih.gov/rss/search/1dmEOdK-P_-UBN_co2XahWMyPwt10E-2wAci7qgyqB1wWIwkJY/?limit=100&utm_campaign=pubmed-2&fc=20240608182355\r\n\r\n((\"Central Nervous System Regeneration\" OR \"Neuroregeneration\" OR \"Neural Regeneration\" OR \"Central Nervous System Repair\") \r\nOR (\"Myelination\" OR \"Remyelination\" OR \"Myelin Repair\" OR \"Oligodendrocyte Differentiation\" OR \"Oligodendrocyte Progenitor Cells\" OR \"Myelin Regeneration\") \r\nOR (\"Stem Cells and Myelin Production\" OR \"Neural Stem Cells\" OR \"Growth Factors for Myelin Regeneration\" OR \"Neurotrophic Factors\" OR \"Glial Cell Line-Derived Neurotrophic Factor\") \r\nOR (\"Gene Therapy for CNS Repair\" OR \"Gene Therapy for Myelination\" OR \"Molecular Targets for Myelin Regeneration\" OR \"Epigenetic Regulation of Myelination\") \r\nOR (\"Pharmacological Agents for CNS Regeneration\" OR \"Drugs Promoting Myelination\" OR \"Neuroprotective Agents\" OR \"Remyelinating Drugs\" OR \"Small Molecules for Myelin Repair\") \r\nOR (\"Novel Treatments for CNS Repair\" OR \"Emerging Therapies for Myelin Regeneration\"))", "team_id": 1 } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Molecular Psychiatry", "authors": [ { "author_id": 172888, "given_name": "Hao", "family_name": "Li", "ORCID": "http://orcid.org/0000-0002-5785-247X", "country": null }, { "author_id": 384545, "given_name": "Zhe", "family_name": "Zhao", "ORCID": "https://orcid.org/0000-0001-5959-9941", "country": null }, { "author_id": 364374, "given_name": "Shaofei", "family_name": "Jiang", "ORCID": null, "country": null }, { "author_id": 397116, "given_name": "Haitao", "family_name": "Wu", "ORCID": "https://orcid.org/0000-0001-8437-3194", "country": null } ], "discovery_date": "2025-04-27T11:25:32.998283Z", "article_subject_relevances": [], "doi": "10.1038/s41380-025-03037-6", "access": "open", "takeaways": "Social stressors can lead to emotional disorders and cognitive impairments. Dysfunctional social behaviors are hallmark symptoms of various neuropsychiatric disorders,", "team_categories": [], "ml_predictions": [] }, { "article_id": 294668, "title": "Porous perspectives: a comprehensive review of medullary sponge kidney", "summary": "CONCLUSION: Further research is warranted to improve our understanding of MSK and develop targeted therapies.", "link": "https://pubmed.ncbi.nlm.nih.gov/40287601/?fc=20240608182355&ff=20250427072511&v=2.18.0.post9+e462414", "published_date": "2025-04-26T10:00:00Z", "sources": [ "PubMed CNS Regenerate" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 2, "subject_name": "CNS Regeneration", "description": "https://pubmed.ncbi.nlm.nih.gov/rss/search/1dmEOdK-P_-UBN_co2XahWMyPwt10E-2wAci7qgyqB1wWIwkJY/?limit=100&utm_campaign=pubmed-2&fc=20240608182355\r\n\r\n((\"Central Nervous System Regeneration\" OR \"Neuroregeneration\" OR \"Neural Regeneration\" OR \"Central Nervous System Repair\") \r\nOR (\"Myelination\" OR \"Remyelination\" OR \"Myelin Repair\" OR \"Oligodendrocyte Differentiation\" OR \"Oligodendrocyte Progenitor Cells\" OR \"Myelin Regeneration\") \r\nOR (\"Stem Cells and Myelin Production\" OR \"Neural Stem Cells\" OR \"Growth Factors for Myelin Regeneration\" OR \"Neurotrophic Factors\" OR \"Glial Cell Line-Derived Neurotrophic Factor\") \r\nOR (\"Gene Therapy for CNS Repair\" OR \"Gene Therapy for Myelination\" OR \"Molecular Targets for Myelin Regeneration\" OR \"Epigenetic Regulation of Myelination\") \r\nOR (\"Pharmacological Agents for CNS Regeneration\" OR \"Drugs Promoting Myelination\" OR \"Neuroprotective Agents\" OR \"Remyelinating Drugs\" OR \"Small Molecules for Myelin Repair\") \r\nOR (\"Novel Treatments for CNS Repair\" OR \"Emerging Therapies for Myelin Regeneration\"))", "team_id": 1 } ], "publisher": "Springer Science and Business Media LLC", "container_title": "International Urology and Nephrology", "authors": [ { "author_id": 407455, "given_name": "Bárbara Almeida", "family_name": "Camolese", "ORCID": null, "country": null }, { "author_id": 407456, "given_name": "Gustavo Santos", "family_name": "Rainato", "ORCID": null, "country": null }, { "author_id": 407457, "given_name": "Isadora Soares Bicalho", "family_name": "Garcia", "ORCID": null, "country": null }, { "author_id": 407458, "given_name": "Naira Kelly", "family_name": "Ribeiro de Almeida", "ORCID": null, "country": null }, { "author_id": 407459, "given_name": "Stella Cardoso", "family_name": "Galante", "ORCID": null, "country": null }, { "author_id": 407460, "given_name": "Vitor Neves", "family_name": "Batista", "ORCID": null, "country": null }, { "author_id": 407461, "given_name": "Anna Luiza Braga", "family_name": "Albuquerque", "ORCID": null, "country": null }, { "author_id": 407462, "given_name": "Pedro Alves Soares", "family_name": "Vaz de Castro", "ORCID": null, "country": null }, { "author_id": 407463, "given_name": "Ana Cristina", "family_name": "Simões e Silva", "ORCID": null, "country": null } ], "discovery_date": "2025-04-27T11:25:28.470940Z", "article_subject_relevances": [], "doi": "10.1007/s11255-025-04531-0", "access": "restricted", "takeaways": "", "team_categories": [], "ml_predictions": [] }, { "article_id": 294667, "title": "Investigating the Mechanisms of Esketamine in Treating Propofol-Induced Cognitive Impairment in Elderly Rats", "summary": "CONCLUSION: By inhibiting the mTOR-BDNF pathway with esketamine, the inhibition of neuronal autophagy ultimately improves the cognitive dysfunction induced by propofol.", "link": "https://pubmed.ncbi.nlm.nih.gov/40287805/?fc=20240608182355&ff=20250427072511&v=2.18.0.post9+e462414", "published_date": "2025-04-27T10:00:00Z", "sources": [ "PubMed CNS Regenerate" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 2, "subject_name": "CNS Regeneration", "description": "https://pubmed.ncbi.nlm.nih.gov/rss/search/1dmEOdK-P_-UBN_co2XahWMyPwt10E-2wAci7qgyqB1wWIwkJY/?limit=100&utm_campaign=pubmed-2&fc=20240608182355\r\n\r\n((\"Central Nervous System Regeneration\" OR \"Neuroregeneration\" OR \"Neural Regeneration\" OR \"Central Nervous System Repair\") \r\nOR (\"Myelination\" OR \"Remyelination\" OR \"Myelin Repair\" OR \"Oligodendrocyte Differentiation\" OR \"Oligodendrocyte Progenitor Cells\" OR \"Myelin Regeneration\") \r\nOR (\"Stem Cells and Myelin Production\" OR \"Neural Stem Cells\" OR \"Growth Factors for Myelin Regeneration\" OR \"Neurotrophic Factors\" OR \"Glial Cell Line-Derived Neurotrophic Factor\") \r\nOR (\"Gene Therapy for CNS Repair\" OR \"Gene Therapy for Myelination\" OR \"Molecular Targets for Myelin Regeneration\" OR \"Epigenetic Regulation of Myelination\") \r\nOR (\"Pharmacological Agents for CNS Regeneration\" OR \"Drugs Promoting Myelination\" OR \"Neuroprotective Agents\" OR \"Remyelinating Drugs\" OR \"Small Molecules for Myelin Repair\") \r\nOR (\"Novel Treatments for CNS Repair\" OR \"Emerging Therapies for Myelin Regeneration\"))", "team_id": 1 } ], "publisher": "Discovery Medicine", "container_title": "Discovery Medicine", "authors": [ { "author_id": 407452, "given_name": "Jieru", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 407453, "given_name": "Guofeng", "family_name": "Xu", "ORCID": null, "country": null }, { "author_id": 323379, "given_name": "Xiaoli", "family_name": "Wang", "ORCID": null, "country": null }, { "author_id": 407454, "given_name": "Leyan", "family_name": "Qiao", "ORCID": null, "country": null } ], "discovery_date": "2025-04-27T11:25:25.873362Z", "article_subject_relevances": [], "doi": "10.24976/Discov.Med.202537195.60", "access": "restricted", "takeaways": "", "team_categories": [], "ml_predictions": [] }, { "article_id": 294666, "title": "Protective Role of Cerium Oxide Nanoparticle Pretreatment in Preventing Pilocarpine-Induced Epileptic Seizures", "summary": "CONCLUSIONS: CNP exhibits anti-epileptic and neuroprotective effects in PILO-induced epilepsy. This protective effect is likely due to the enhancement of the NRF2 signaling pathway, which regulates antioxidant enzymes, improves neuronal defense mechanisms against oxidative stress, and reduces seizure-induced neuronal damage.", "link": "https://pubmed.ncbi.nlm.nih.gov/40287807/?fc=20240608182355&ff=20250427072511&v=2.18.0.post9+e462414", "published_date": "2025-04-27T10:00:00Z", "sources": [ "PubMed CNS Regenerate" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 2, "subject_name": "CNS Regeneration", "description": "https://pubmed.ncbi.nlm.nih.gov/rss/search/1dmEOdK-P_-UBN_co2XahWMyPwt10E-2wAci7qgyqB1wWIwkJY/?limit=100&utm_campaign=pubmed-2&fc=20240608182355\r\n\r\n((\"Central Nervous System Regeneration\" OR \"Neuroregeneration\" OR \"Neural Regeneration\" OR \"Central Nervous System Repair\") \r\nOR (\"Myelination\" OR \"Remyelination\" OR \"Myelin Repair\" OR \"Oligodendrocyte Differentiation\" OR \"Oligodendrocyte Progenitor Cells\" OR \"Myelin Regeneration\") \r\nOR (\"Stem Cells and Myelin Production\" OR \"Neural Stem Cells\" OR \"Growth Factors for Myelin Regeneration\" OR \"Neurotrophic Factors\" OR \"Glial Cell Line-Derived Neurotrophic Factor\") \r\nOR (\"Gene Therapy for CNS Repair\" OR \"Gene Therapy for Myelination\" OR \"Molecular Targets for Myelin Regeneration\" OR \"Epigenetic Regulation of Myelination\") \r\nOR (\"Pharmacological Agents for CNS Regeneration\" OR \"Drugs Promoting Myelination\" OR \"Neuroprotective Agents\" OR \"Remyelinating Drugs\" OR \"Small Molecules for Myelin Repair\") \r\nOR (\"Novel Treatments for CNS Repair\" OR \"Emerging Therapies for Myelin Regeneration\"))", "team_id": 1 } ], "publisher": "Discovery Medicine", "container_title": "Discovery Medicine", "authors": [ { "author_id": 285949, "given_name": "Dan", "family_name": "Yang", "ORCID": null, "country": null }, { "author_id": 315291, "given_name": "Shuangfeng", "family_name": "Yang", "ORCID": null, "country": null }, { "author_id": 407450, "given_name": "Jingya", "family_name": "Deng", "ORCID": null, "country": null }, { "author_id": 407451, "given_name": "Xiyue", "family_name": "Fan", "ORCID": null, "country": null }, { "author_id": 328475, "given_name": "Guohui", "family_name": "Jiang", "ORCID": "http://orcid.org/0000-0002-1267-2221", "country": null }, { "author_id": 229328, "given_name": "Fei", "family_name": "Yang", "ORCID": "http://orcid.org/0009-0006-8111-043X", "country": null }, { "author_id": 286702, "given_name": "Xiaoming", "family_name": "Wang", "ORCID": null, "country": null } ], "discovery_date": "2025-04-27T11:25:22.189645Z", "article_subject_relevances": [], "doi": "10.24976/Discov.Med.202537195.62", "access": "restricted", "takeaways": "", "team_categories": [], "ml_predictions": [] }, { "article_id": 294665, "title": "Trauma Burden Affected People with Multiple Sclerosis During SARS-CoV-2 Pandemic", "summary": "<jats:p>Background/Objectives: Trauma is a psychological injury resulting from a distressing or overwhelming event. The SARS-CoV-2 pandemic has been disruptive and traumatic for many people with multiple sclerosis (pwMS). The relationship between patient characteristics and trauma in pwMS during the pandemic has not yet been thoroughly explored. The aim of this bicentric prospective cohort study was to analyze the prevalence and development of probable post-traumatic stress disorder (PTSD) among pwMS during the SARS-CoV-2 pandemic and to identify patient parameters associated with this condition. Methods: We have assessed pwMS for probable PTSD before and after the approval of the first SARS-CoV-2 vaccines in Germany using an adapted version of the Trauma Screening Questionnaire (TSQ). We compared pwMS with probable PTSD (TSQ sum score ≥ 6) with those without probable PTSD (TSQ sum score < 6) regarding sociodemographic and MS-specific clinical characteristics, polypharmacy status, comorbidities, anxiety/depression levels, personality traits, mental/physical/social burden, and general vaccination willingness. Results: Out of the 149 pwMS included, 8.1% were identified as having probable PTSD. These patients had significantly higher rates of pre-pandemic abnormal anxiety (66.7% vs. 18.5%, p < 0.001) and depression scores (45.5% vs. 12.6%, p = 0.013). The patients with probable PTSD exhibited a distinct personality profile, with significantly higher neuroticism and harm avoidance scores and lower conscientiousness, cooperativeness, and self-directedness scores. They were also significantly more likely to report severe or very severe mental/physical/social burdens during the pandemic compared to those without probable PTSD (p ≤ 0.045). Conclusions: Medical and social services should be provided to support patients who experienced serious stress or trauma. The development of concepts for education and vaccination procedures should be accompanied by comprehensive and clear communication that recognizes individual risk factors and addresses possible concerns with evidence-based and convincing arguments.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/40283495/?fc=20240915071900&ff=20250426193144&v=2.18.0.post9+e462414", "published_date": "2025-04-26T10:00:00Z", "sources": [ "PubMed for MS" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "MDPI AG", "container_title": "Journal of Clinical Medicine", "authors": [ { "author_id": 407447, "given_name": "Felicita", "family_name": "Heidler", "ORCID": "https://orcid.org/0000-0001-7948-958X", "country": null }, { "author_id": 407448, "given_name": "Michael", "family_name": "Hecker", "ORCID": "https://orcid.org/0000-0001-7015-3094", "country": null }, { "author_id": 178036, "given_name": "Niklas", "family_name": "Frahm", "ORCID": "http://orcid.org/0000-0002-4655-774X", "country": null }, { "author_id": 277632, "given_name": "Julia", "family_name": "Baldt", "ORCID": null, "country": null }, { "author_id": 277634, "given_name": "Barbara", "family_name": "Streckenbach", "ORCID": null, "country": null }, { "author_id": 317584, "given_name": "Janina", "family_name": "Meißner", "ORCID": null, "country": null }, { "author_id": 292504, "given_name": "Katja", "family_name": "Burian", "ORCID": null, "country": null }, { "author_id": 407449, "given_name": "Silvan Elias", "family_name": "Langhorst", "ORCID": "https://orcid.org/0000-0001-8286-693X", "country": null }, { "author_id": 277633, "given_name": "Pegah", "family_name": "Mashhadiakbar", "ORCID": null, "country": null }, { "author_id": 229763, "given_name": "Jörg", "family_name": "Richter", "ORCID": "http://orcid.org/0000-0002-5823-9618", "country": null }, { "author_id": 319159, "given_name": "Uwe Klaus", "family_name": "Zettl", "ORCID": "http://orcid.org/0000-0002-6348-1759", "country": null } ], "discovery_date": "2025-04-26T23:32:53.924120Z", "article_subject_relevances": [], "doi": "10.3390/jcm14082665", "access": "open", "takeaways": "The SARS-CoV-2 pandemic has been traumatic for people with multiple sclerosis (pwMS). The relationship between patient characteristics and trauma in pwMS during the pandemic hasn't been thoroughly explored. 8.1% of those with probable PTSD were found to have significantly higher rates of pre-pandemic abnormal anxiety and depression. They were also more likely to report severe or very severe mental/physical/social burdens.", "team_categories": [], "ml_predictions": [] }, { "article_id": 294664, "title": "Evaluation of the Utility of Hybrid PET/MR Neuroimaging in Inflammatory Demyelination and Encephalitis", "summary": "<jats:p>With the increased availability of hybrid PET/MRI in recent years, this method is increasingly used for neuroimaging in clinical practice. It combines the advantages of MRI (including high-resolution imaging of intracerebral lesions and data provided from specialised MRI sequences) with the benefits of PET, which visualises functional alterations in the brain, as well as assesses the myelin quantity changes and the severity of inflammation. The use of PET/MRI may help to eliminate the limitations of MRI indicated in imaging demyelinating inflammatory diseases (such as low specificity in imaging demyelination and a weak correlation of findings with clinical symptoms), as well as insufficient sensitivity in detecting lesions present in encephalitis. In addition to supporting the diagnosis of encephalitis, PET/MRI facilitates monitoring of the disease course and assessing the treatment efficacy of inflammatory demyelinating diseases and encephalitis, as well as evaluating the risk of multiple sclerosis relapse. Further multi-centre longitudinal studies are necessary to assess the real clinical potential of PET/MRI among patients with inflammatory demyelination or encephalitis. In addition to MS and AIE, these studies should also include other inflammatory demyelinating diseases (ADEM, NMO, NMOSD, and MOGAD) as well as encephalitis of viral and parasitic aetiology.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/40283565/?fc=20240915071900&ff=20250426193144&v=2.18.0.post9+e462414", "published_date": "2025-04-26T10:00:00Z", "sources": [ "PubMed for MS" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "MDPI AG", "container_title": "Journal of Clinical Medicine", "authors": [ { "author_id": 407442, "given_name": "Radosław", "family_name": "Zawadzki", "ORCID": null, "country": null }, { "author_id": 407443, "given_name": "Maciej", "family_name": "Naumowicz", "ORCID": null, "country": null }, { "author_id": 407444, "given_name": "Magdalena", "family_name": "Zalewska", "ORCID": null, "country": null }, { "author_id": 407445, "given_name": "Joanna", "family_name": "Zajkowska", "ORCID": "https://orcid.org/0000-0002-5695-1652", "country": null }, { "author_id": 407446, "given_name": "Bożena", "family_name": "Kubas", "ORCID": null, "country": null } ], "discovery_date": "2025-04-26T23:32:51.473341Z", "article_subject_relevances": [], "doi": "10.3390/jcm14082736", "access": "open", "takeaways": "Hybrid PET/MRI is increasingly used for neuroimaging in clinical practice. It combines the advantages of MRI with the benefits of PET. It visualises functional alterations in the brain and assesses the myelin quantity changes and the severity of inflammation. It also supports the diagnosis of encephalitis and monitoring of the disease course.", "team_categories": [], "ml_predictions": [] } ] }